XENE FY 2013 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M+91.2% YoY

Gross Profit

$21M77.3% margin

Operating Income

$10M35.5% margin

Net Income

$12M44.0% margin

EPS (Diluted)

$0.39

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$648,000

Balance Sheet

Total Assets

$54M

Total Liabilities

$30M

Stockholders' Equity

$24M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$14M	+91.2%
Gross Profit	$21M	$7M	+202.6%
Operating Income	$10M	-$3M	+408.0%
Net Income	$12M	-$4M	+379.7%